Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Allogene Therapeutics, Inc. (ALLO) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Allogene Therapeutics, Inc. (ALLO), most recent 12 months reported: revenue $0, net loss $165.49M, free cash flow -$102.6M. Latest balance sheet on file: liquid cash $332.6M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): Creative Medical Technology Holdings, Inc. · Acumen Pharmaceuticals, Inc. · Abpro Holdings, Inc. · AGENTIX CORP. · Adaptin Bio, Inc. · ARMATA PHARMACEUTICALS, INC. · Artiva Biotherapeutics, Inc. · Aura Biosciences, Inc.

Stock screener

Watchlist